T Cell News and Research

Latest T Cell News and Research

Researchers demonstrate how insulin prepares cells for glucose uptake

Using high-resolution microscopy, researchers at the National Institutes of Health have shown how insulin prompts fat cells to take in glucose in a rat model. The findings were reported in the Sept. 8 issue of the journal Cell Metabolism.

9 Sep 2010

Researchers reveal surface protein alteration mechanism of mycoplasma bacteria

Pathogenic bacteria have evolved a variety of mechanisms to avoid being killed by the immune systems of the humans and animals they invade. Among the most sophisticated is that practised by mycoplasmas, which regularly change their surface proteins to confuse the immune system. Recent work in the group of Renate Rosengarten and Rohini Chopra-Dewasthaly at the University of Veterinary Medicine, Vienna has revealed surprising new details of the way they do so and at the same time raised important evolutionary questions.

9 Sep 2010

Micro-RNAs programmed cells can lead to malignant growth

Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.

9 Sep 2010

Scientists discover natural mechanism to discard amyloid protein

Chemists at the University of California, San Diego, have identified how a protein that accumulates in the brains of people with Alzheimer's disease interferes with the ability of cells to get rid of debris. They also found a natural mechanism by which this protein, amyloid beta, itself may be discarded.

9 Sep 2010

NIH awards second $8 million grant for research into health effects of botanical estrogens

An ongoing research initiative into the health effects of botanical estrogens will get an $8 million boost from the National Institutes of Health.

9 Sep 2010

Federal judge refuses to lift order blocking federal funding for stem cell research

The Associated Press: "A federal judge on Tuesday refused to lift his order blocking federal funding for some stem cell research, saying that a 'parade of horribles' predicted by federal officials would not happen. Medical researchers value stem cells because they are master cells that can turn into any tissue of the body.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

9 Sep 2010

ARID1A gene links ovarian cancer to endometriosis

Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.

9 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

First Edition: September 8, 2010

In today's headlines, reports about how health reform is playing on the campaign trail and the latest on health insurance premium hikes.

8 Sep 2010

ProteaBio concludes agreement with George Washington University to commercialize LAESI technology

ProteaBio Europe SAS, a leading developer of new technology, announced today that the company has concluded an exclusive, worldwide license agreement with George Washington University for commercial rights to a new technology that provides rapid identification of a broad range of chemicals and biomolecules.

8 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Researchers find blebbistatin chemically inhibits NMII, enhances survival of stem cells

Human pluripotent stem (hPS) cells can generate any given cell type in the adult human body, which is why they are of interest to stem cell scientists working on finding therapies for spinal cord injuries, Parkinson's disease, burns, heart disease, diabetes, arthritis, and other ailments.

8 Sep 2010

Scientists gather to present research findings at ASHG 2010 Meeting

The world's top scientists and clinicians in the human genetics field will gather in Washington, D.C., to present their latest research findings at the 60th Annual Meeting of the American Society of Human Genetics, from Tuesday, November 2, through Saturday, November 6, 2010, at the Walter E. Washington Convention Center in D.C.

8 Sep 2010

KRN cell transfer model provides novel opportunity for rheumatoid arthritis research

Current research provides a novel model for rheumatoid arthritis research. The related report by LaBranche et al, "Characterization of the KRN cell transfer model of rheumatoid arthritis, a chronic yet synchronized version of the K/BxN mouse," appears in the September 2010 issue of The American Journal of Pathology.

8 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Synthetic derivative of Retinoic acid can induce cell death

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25 % of cases and which can lead to death. The development of 4-HPR, a synthetic derivative of RA, has meant a considerable advance due to its greater efficacy compared to its predecessor.

8 Sep 2010

T Cell News and Research

Latest T Cell News and Research

Researchers demonstrate how insulin prepares cells for glucose uptake

Researchers reveal surface protein alteration mechanism of mycoplasma bacteria

Micro-RNAs programmed cells can lead to malignant growth

Scientists discover natural mechanism to discard amyloid protein

NIH awards second $8 million grant for research into health effects of botanical estrogens

Federal judge refuses to lift order blocking federal funding for stem cell research

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

ARID1A gene links ovarian cancer to endometriosis

Zyngenia completes $15M Series A financing extension from NEA

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

First Edition: September 8, 2010

ProteaBio concludes agreement with George Washington University to commercialize LAESI technology

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

Researchers find blebbistatin chemically inhibits NMII, enhances survival of stem cells

Scientists gather to present research findings at ASHG 2010 Meeting

KRN cell transfer model provides novel opportunity for rheumatoid arthritis research

Silence Therapeutics receives two patents for RNA interference therapeutics

Synthetic derivative of Retinoic acid can induce cell death

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in